Theravance Biopharma, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Theravance Biopharma, Inc. (TBPH) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss of $79.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $79.00K.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $64.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $5.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $11.00K.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss |
|---|---|
| 2026-06-30 | $79.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $64.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $5.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $11.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $12.00K 10-Q · filed 2025-08-13 |
| 2024-12-31 | $3.00K 10-K · filed 2026-03-23 |
| 2024-06-30 | $22.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $41.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $69.00K 10-K · filed 2025-03-07 |
| 2023-09-30 | $225.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $286.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $28.00K 10-Q · filed 2023-05-10 |
| 2022-12-31 | $27.00K 10-K · filed 2024-03-01 |
| 2022-09-30 | $121.00K 10-Q · filed 2022-11-09 |
| 2022-06-30 | $47.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $34.00K 10-Q · filed 2022-05-06 |
| 2021-12-31 | $5.00K 10-K · filed 2023-03-01 |
| 2021-03-31 | $1.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $6.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $1.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $3.00K 10-Q · filed 2020-08-10 |
| 2019-12-31 | $3.00K 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |